Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/30/2891104/0/en/Qualigen-Therapeutics-Inc-Received-Nasdaq-Notice-of-a-Delisting-Determination.html
https://www.globenewswire.com/news-release/2024/04/16/2863440/0/en/Marizyme-Enters-Into-Co-Development-Agreement-With-Qualigen-Therapeutics-for-the-Commercialization-of-FDA-Cleared-DuraGraft.html
https://www.globenewswire.com/news-release/2024/04/10/2860669/0/en/Qualigen-Therapeutics-Novel-Direct-Pan-RAS-Inhibitors-Presented-at-American-Association-of-Cancer-Research-AACR-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/09/2859900/0/en/Qualigen-Therapeutics-Announces-Poster-Featuring-Positive-Early-Clinical-Experience-with-QN-302-a-Novel-First-in-Class-G-Quadruplex-Experimental-Anti-Cancer-Drug-at-the-American-As.html
https://www.globenewswire.com//news-release/2023/11/14/2780571/0/en/Qualigen-Therapeutics-Provides-Corporate-Update-for-Third-Quarter-and-To-Date-2023.html
https://www.globenewswire.com//news-release/2023/11/07/2775116/0/en/Qualigen-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-1a-Clinical-Trial-of-QN-302-for-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html
https://www.globenewswire.com//news-release/2023/10/23/2764724/0/en/Poster-Highlighting-Qualigen-Therapeutics-Pan-RAS-Inhibitor-Platform-Presented-at-AACR-Special-Conference-Advances-in-Breast-Cancer.html
https://www.globenewswire.com//news-release/2023/09/27/2750380/0/en/Qualigen-Therapeutics-Presents-Scientific-Data-on-QN-302-at-AACR-Special-Conference-Pancreatic-Cancer-2023.html
https://www.globenewswire.com//news-release/2023/08/17/2727243/0/en/Qualigen-Therapeutics-Partners-with-TD2-for-Phase-1-Clinical-Development-of-QN-302-for-the-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html
https://www.globenewswire.com/news-release/2023/08/15/2725473/0/en/Qualigen-Therapeutics-Inc-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ending-June-30-2023.html